期刊
CLINICAL INFECTIOUS DISEASES
卷 64, 期 7, 页码 972-980出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/cix034
关键词
ESBLs; carbapenems; cephamycins; cefepime; piperacillin-tazobactam
资金
- National Institutes of Health [1K23AI127935]
- inhealth Pilot Project Discovery Program
The continued rise in infections caused by extended-spectrum beta-lactamase (ESBL)-producing pathogens is recognized globally as one of the most pressing concerns facing the healthcare community. Carbapenems are widely regarded as the antibiotics of choice for the treatment of ESBL-producing infections, even when in vitro activity to other beta-lactams has been demonstrated. However, indiscriminant carbapenem use is not without consequence, and carbapenem overuse has contributed to the emergence of carbapenem-resistant Enterobacteriaceae. The use of non-carbapenem beta-lactams for the treatment of ESBL infections has yielded conflicting results. In this review, we discuss the available data for the use of cephamycins, cefepime, piperacillin-tazobactam, ceftolozane-tazobactam, and ceftazidime-avibactam for the treatment of ESBL infections.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据